RM-493

DRUG3 trials

Sponsors

Rhythm Pharmaceuticals, Inc., Charite University, Berlin, Germany

Conditions

Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene MutationMorbid ObesityObeseObesityOverweight

Phase 1

Effects of RM-493 on Energy Expenditure in Obese Individuals

CompletedNCT01867437

Rhythm Pharmaceuticals, Inc.Morbid Obesity, Obesity

Start: 2013-05-31End: 2014-03-31Updated: 2017-04-20

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers

CompletedNCT02431442

Rhythm Pharmaceuticals, Inc.Obese, Overweight

Start: 2012-01-31End: 2014-01-31Updated: 2015-05-01

Phase 2

RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients

Charite University, Berlin, GermanyHomozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation

Start: 2015-01-31End: 2018-07-31Target: 10Updated: 2016-02-22

Related Papers

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency

Journal of the Endocrine Society2021-05-015 citations